Details of the Drug Reposition

General Information of This Drug (ID: DMG77O2)

Drug Name
Efavaleukin alfa   DMG77O2
Synonyms AMG592
Drug Type
Fusion Protein

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Systemic lupus erythematosus DISI1SZ7 4A40.0 Phase 2 [1]
Ulcerative colitis DIS8K27O DD71 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04680637) A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04987307) A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.